Muscle Spasticity
A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a free interval) followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)
Drugs by status
Approved for this indication (5)
Phase 4 trials (10)
Phase 3 trials (4)
Phase 2 trials (13)
Phase 1 trials (3)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (35)
- Solstice Neurosciences
- Ipsen
- Allergan
- Chugai
- GW Pharmaceuticals Ltd.
- Medy-Tox
- Merz
- Daewoong Pharmaceutical Co. LTD.
- Cornell University
- Georgetown University
- Norwegian University of Science and Technology
- Osaka University
- Seoul National University
- The Hospital of Vestfold
- University of Houston
- University Hospital of North Norway
- University of Bergen
- Yonsei University
- Vanderbilt University
- Zhejiang University
- Icahn School of Medicine at Mount Sinai
- Fundació IMIM - Parc de Salut Mar
- Jiao Tong University
- University of Toulouse
- MS Center of Northeastern New York
- CHU Mont-Godinne
- Catholic University of Korea
- University of Texas at Houston
- Bobath Memorial Hospital
- Landeskrankenhaus Hochzirl, Zirl (Austria)
- +5 more
Organization Involved with Phase 3 Indications (46)
- Acorda Therapeutics
- Impax Laboratories
- Elan Pharmaceuticals
- Almirall
- GlaxoSmithKline
- Hugel
- Mallinckrodt
- Bionorica
- Weleda AG
- Maastricht University
- Chang Gung University
- University of London
- Federal University of Bahia
- Federal University of Rio Grande do Sul
- Institut fur Klinische Forschung, Germany
- Newcastle University
- St. Marianna University School of Medicine
- University of East Anglia
- University of Milan
- University of Padova
- University of Pavia
- University of Plymouth
- University of Tokushima
- Université catholique de Louvain
- University of Ulsan
- Tsinghua University
- GW Research
- University of Limoges
- US WorldMeds
- University of Lyon
- +16 more
Organization Involved with Phase 2 Indications (40)
- XenoPort, Inc.
- Bausch Health Companies
- Avigen
- ASIS Corporation
- Novartis
- Hamilton Health Sciences Corporation
- Indivior Inc.
- Revance Therapeutics, Inc.
- Teva
- Canbex Therapeutics Ltd
- National Institutes of Health (NIH)
- University of Manitoba
- Alborz Medical University
- Duke University
- Hoosier Cancer Research Network
- Hormozgan University of Medical Sciences
- Institut National de la Santé Et de la Recherche Médicale, France
- Keele University
- New York University
- Thomas Jefferson University
- University of Tehran
- University of Toronto
- University of Alberta
- University of Birmingham
- University of Virginia
- Fujian Medical University
- Tel Aviv University
- University of California, Davis
- University of California, San Diego
- AUTOMATIC SUBDERMAL INJECTOR SYSTEM, INC
- +10 more
Organization Involved with Phase 1 Indications (11)
- Merck
- Huons Co.,Ltd.
- INC Research
- National Institute of Neurological Disorders and Stroke (NINDS)
- Cayetano Heredia University
- University Ramon Llull
- Instituto de Medicina Tropical Alexander von Humboldt
- Association of Cerebral Palsy
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
- Cerebral Palsy Association
- Department of Physical Medicine&Rehabilitation
Organization Involved with Other Experimental Indications (14)
- Ege University
- Marmara University
- Northwestern University
- Sunnaas Rehabilitation Hospital
- University of Nove de Julho
- University of Copenhagen
- University of Delaware
- Biomedical Research Institute of New Mexico
- University of Ljubljana
- University of Gothenburg
- Department of Veteran Affairs
- New York Presbyterian Hospital
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
- PharmaHemp